Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: Safety and efficacy

Haemophilia

Volumn 19, Issue 5, 2013, Pages 691-697

  Lentz, S R ^a   Misgav, M ^b   Ozelo, M ^c   Salek S Z ^d   Veljkovic, D ^e   Recht, M ^f   Cerqueira, M ^g   Tiede, A ^h   Brand, B ⁱ   Mancuso, M E ^j   Seremetis, S ^k   Lindblom, A ^l   Martinowitz, U ^b  

^a UNIVERSITY OF IOWA   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d KBC Zagreb   (Croatia)

^e Mother and Child Health Care Institute of Serbia   (Serbia)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g HEMORIO   (Brazil)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^k NOVO NORDISK INC   (United States)

^l NOVO NORDISK A S   (Denmark)

more..

Author keywords

Haemophilia A; Prophylaxis; Recombinant factor VIII; Turoctocog alfa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEMOPHILIA A; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SINUS TACHYCARDIA; TREATMENT OUTCOME;

HAEMOPHILIA A; PROPHYLAXIS; RECOMBINANT FACTOR VIII; TUROCTOCOG ALFA;

ADOLESCENT; ADULT; AGED; CHILD; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84883052880     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12159     Document Type: Article

References (17)

1. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
2. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
3. Christiansen ML, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
4. ®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854-9.
5. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
6. EMA. Committee for medicinal products for human use (CHMP), guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products, EMA/CHMP/BPWP/144533/2009. 2011.
7. WMA. Declaration of Helsinki - ethical principles for medical research involving human subjects. 2010.
8. ICH. Tripartite harmonised guideline: good clinical practice: consolidated guideline (E6). 2010.
9. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
10. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den BM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
11. Kulkarni R, Abdul Karim F, Glamocanin S et al. Results from a large multinational clinical trial (guardian 3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. Haemophilia 2013; 19: 698-705.
12. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
13. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
14. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
15. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
16. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
17. Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005; 11: 444-51.